Loading
Two opposite ways of rescheduling the same drugs: dose-dense gives standard doses more often (every two weeks instead of three, supported by growth factors) to deny the tumour recovery time; metronomic gives small doses continuously to attack tumour blood vessels with little toxicity.
Dose-dense adjuvant chemotherapy improved survival in breast cancer (CALGB 9741, EBCTCG meta-analysis) and interval-compressed VDC/IE is standard in Ewing sarcoma; it needs G-CSF support. Metronomic oral chemotherapy (capecitabine, cyclophosphamide, methotrexate, vinorelbine) exploits anti-angiogenic and immune effects, is cheap and well tolerated, and is used in maintenance (CM in triple-negative breast, SYSUCC-001) and low-resource settings such as Tata Memorial's head and neck trials. Both are examples of gaining efficacy from schedule rather than new molecules.
Showing the technology this term belongs to: Cytotoxic chemotherapy.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy.
Shares Maintenance therapy, Head and neck squamous cell carcinoma.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Head and neck squamous cell carcinoma.
Shares Regimen and cycles, Neutropenia.